Methadone Attenuated THC Timing-Task Errors in Pigeons Without Resolving the Mechanism

A 1980 pigeon study found that repeated higher methadone doses attenuated THC-related errors on a temporal-discrimination task. The authors left cross-tolerance and antagonism as possible explanations rather than identifying one proven mechanism.

The task measured a defined choice

Birds chose between keys after short or long light presentations, with food following correct choices. THC reduced accuracy in a dose-related manner, with a larger effect on long-duration trials. The endpoint was discrimination accuracy, not a general measure of alertness or subjective intoxication.

Dose history changed the comparison

Higher repeated methadone doses produced more attenuation of selected THC effects than a lower methadone dose. Methadone alone affected accuracy when its dose changed. These observations make the dosing history essential to interpreting the combination rather than assigning one fixed interaction to the two compounds.

Two explanations remained open

A smaller challenge response could reflect adaptation shared across drugs or another interaction affecting expression of the THC response. The abstract did not establish which account was responsible. Calling the result cross-tolerance without that qualification would overstate the evidence.

Interpreting the evidence

This laboratory finding does not show that methadone protects people from cannabis impairment or supplies a safe combination. It supports a narrow statement about an experimental timing task, with dose, species and unresolved mechanism retained.

Related reading: interpreting cannabis tolerance claims.

Research reference

Daniel SA; Thompson T (1980). Methadone-induced attenuation of the effects of delta 9-tetrahydrocannabinol on temporal discrimination in pigeons. The Journal of pharmacology and experimental therapeutics. PubMed research record.

This analysis draws on the supplied abstract.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

APD371 Maintained a Pain-Response Effect for Five Days in a Preclinical Development Study

A 2017 drug-discovery report described APD371, a selective CB2 agonist, maintaining its effect during a five-day rat osteoarthritis-pain protocol. That short preclinical finding is different from established long-term clinical efficacy. The report concerned selection of a development candidate The authors considered receptor efficacy, pharmacokinetics and pharmaceutical properties alongside an oral…

Spread the love

Read Article: APD371 Maintained a Pain-Response Effect for Five Days in a Preclinical Development Study

Two Biased CB2 Agonists Had Different Durability in a Rat Osteoarthritis Experiment

A 2021 rat study found sustained pain-response effects with JWH133 while another CB2 agonist lost efficacy after two days under its repeated-treatment protocol. Shared receptor targeting did not establish equal durability. The compounds were compared in a defined model The experiment used chemically induced osteoarthritis and measured pressure responses and…

Spread the love

Read Article: Two Biased CB2 Agonists Had Different Durability in a Rat Osteoarthritis Experiment

An Acute Cannabis Review Treated Neurocognitive Response as a Multi-Factor Question

A 2021 review argued that acute neurocognitive responses to cannabis vary with biological, pharmacological and exposure-related factors. A product label or use-frequency category alone cannot capture all the determinants discussed. The review considered interacting sources of variation It discussed brain-network activity, formulation, use frequency and differences between therapeutic and recreational…

Spread the love

Read Article: An Acute Cannabis Review Treated Neurocognitive Response as a Multi-Factor Question

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us